Daiichi Sankyo’s Asubio Pharma Allocates $102 Million To Research Plant
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo subsidiary Asubio Pharma plans to spend $102 million to build a research facility near Kobe. Asubio planned the facility to be located near the world's fastest supercomputer expected to be available next year. The Daiichi Sankyo subsidiary already specializes in bio-based treatments for various ailments. Its facility is to be among one of 130 drug research and development facilities on Kobe's Port Island. (Click here for more - a subscription may be required
You may also be interested in...
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.